The global market for Gram-Negative Bacterial Infection Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Gram-negative bacteria generally refer to bacteria that show red in the gram-negative staining reaction.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Gram-Negative Bacterial Infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gram-Negative Bacterial Infection Therapeutics.

The Gram-Negative Bacterial Infection Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gram-Negative Bacterial Infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gram-Negative Bacterial Infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Gram-Negative Bacterial Infection Therapeutics Market Report

Report Metric	Details
Report Name	Gram-Negative Bacterial Infection Therapeutics Market
CAGR	5%
Segment by Type	Enteral Treatment Parenteral Treatment Topical Treatment
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Baxter, Sanofi, GlaxoSmithKline, Novartis, Pfizer, Takeda, Nektar Therapeutics, Sumitomo, Targeted Genetics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gram-Negative Bacterial Infection Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Gram-Negative Bacterial Infection Therapeutics Market report?

Ans: The main players in the Gram-Negative Bacterial Infection Therapeutics Market are Baxter, Sanofi, GlaxoSmithKline, Novartis, Pfizer, Takeda, Nektar Therapeutics, Sumitomo, Targeted Genetics

What are the Application segmentation covered in the Gram-Negative Bacterial Infection Therapeutics Market report?

Ans: The Applications covered in the Gram-Negative Bacterial Infection Therapeutics Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Gram-Negative Bacterial Infection Therapeutics Market report?

Ans: The Types covered in the Gram-Negative Bacterial Infection Therapeutics Market report are Enteral Treatment, Parenteral Treatment, Topical Treatment

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Enteral Treatment

1.2.3 Parenteral Treatment

1.2.4 Topical Treatment

1.3 Market by Application

1.3.1 Global Gram-Negative Bacterial Infection Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Perspective (2020-2031)

2.2 Global Gram-Negative Bacterial Infection Therapeutics Growth Trends by Region

2.2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Gram-Negative Bacterial Infection Therapeutics Market Dynamics

2.3.1 Gram-Negative Bacterial Infection Therapeutics Industry Trends

2.3.2 Gram-Negative Bacterial Infection Therapeutics Market Drivers

2.3.3 Gram-Negative Bacterial Infection Therapeutics Market Challenges

2.3.4 Gram-Negative Bacterial Infection Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue

3.1.1 Global Top Gram-Negative Bacterial Infection Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Gram-Negative Bacterial Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Gram-Negative Bacterial Infection Therapeutics Revenue

3.4 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio

3.4.1 Global Gram-Negative Bacterial Infection Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gram-Negative Bacterial Infection Therapeutics Revenue in 2024

3.5 Global Key Players of Gram-Negative Bacterial Infection Therapeutics Head office and Area Served

3.6 Global Key Players of Gram-Negative Bacterial Infection Therapeutics, Product and Application

3.7 Global Key Players of Gram-Negative Bacterial Infection Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Type

4.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2026-2031)

5 Gram-Negative Bacterial Infection Therapeutics Breakdown Data by Application

5.1 Global Gram-Negative Bacterial Infection Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Gram-Negative Bacterial Infection Therapeutics Market Size (2020-2031)

6.2 North America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025)

6.4 North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Gram-Negative Bacterial Infection Therapeutics Market Size (2020-2031)

7.2 Europe Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025)

7.4 Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size (2020-2031)

9.2 Latin America Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Baxter

11.1.1 Baxter Company Details

11.1.2 Baxter Business Overview

11.1.3 Baxter Gram-Negative Bacterial Infection Therapeutics Introduction

11.1.4 Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.1.5 Baxter Recent Development

11.2 Sanofi

11.2.1 Sanofi Company Details

11.2.2 Sanofi Business Overview

11.2.3 Sanofi Gram-Negative Bacterial Infection Therapeutics Introduction

11.2.4 Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.2.5 Sanofi Recent Development

11.3 GlaxoSmithKline

11.3.1 GlaxoSmithKline Company Details

11.3.2 GlaxoSmithKline Business Overview

11.3.3 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Introduction

11.3.4 GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.3.5 GlaxoSmithKline Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Gram-Negative Bacterial Infection Therapeutics Introduction

11.4.4 Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Gram-Negative Bacterial Infection Therapeutics Introduction

11.5.4 Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Takeda

11.6.1 Takeda Company Details

11.6.2 Takeda Business Overview

11.6.3 Takeda Gram-Negative Bacterial Infection Therapeutics Introduction

11.6.4 Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.6.5 Takeda Recent Development

11.7 Nektar Therapeutics

11.7.1 Nektar Therapeutics Company Details

11.7.2 Nektar Therapeutics Business Overview

11.7.3 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Introduction

11.7.4 Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.7.5 Nektar Therapeutics Recent Development

11.8 Sumitomo

11.8.1 Sumitomo Company Details

11.8.2 Sumitomo Business Overview

11.8.3 Sumitomo Gram-Negative Bacterial Infection Therapeutics Introduction

11.8.4 Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.8.5 Sumitomo Recent Development

11.9 Targeted Genetics

11.9.1 Targeted Genetics Company Details

11.9.2 Targeted Genetics Business Overview

11.9.3 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Introduction

11.9.4 Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

11.9.5 Targeted Genetics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Enteral Treatment

Table 3. Key Players of Parenteral Treatment

Table 4. Key Players of Topical Treatment

Table 5. Global Gram-Negative Bacterial Infection Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2020-2025)

Table 9. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2026-2031)

Table 11. Gram-Negative Bacterial Infection Therapeutics Market Trends

Table 12. Gram-Negative Bacterial Infection Therapeutics Market Drivers

Table 13. Gram-Negative Bacterial Infection Therapeutics Market Challenges

Table 14. Gram-Negative Bacterial Infection Therapeutics Market Restraints

Table 15. Global Gram-Negative Bacterial Infection Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players (2020-2025)

Table 17. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2024)

Table 18. Ranking of Global Top Gram-Negative Bacterial Infection Therapeutics Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Gram-Negative Bacterial Infection Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Gram-Negative Bacterial Infection Therapeutics, Product and Application

Table 22. Global Key Players of Gram-Negative Bacterial Infection Therapeutics, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2020-2025)

Table 26. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Type (2026-2031)

Table 28. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2020-2025)

Table 30. Global Gram-Negative Bacterial Infection Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share by Application (2026-2031)

Table 32. North America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 47. Baxter Company Details

Table 48. Baxter Business Overview

Table 49. Baxter Gram-Negative Bacterial Infection Therapeutics Product

Table 50. Baxter Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 51. Baxter Recent Development

Table 52. Sanofi Company Details

Table 53. Sanofi Business Overview

Table 54. Sanofi Gram-Negative Bacterial Infection Therapeutics Product

Table 55. Sanofi Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 56. Sanofi Recent Development

Table 57. GlaxoSmithKline Company Details

Table 58. GlaxoSmithKline Business Overview

Table 59. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Product

Table 60. GlaxoSmithKline Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 61. GlaxoSmithKline Recent Development

Table 62. Novartis Company Details

Table 63. Novartis Business Overview

Table 64. Novartis Gram-Negative Bacterial Infection Therapeutics Product

Table 65. Novartis Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 66. Novartis Recent Development

Table 67. Pfizer Company Details

Table 68. Pfizer Business Overview

Table 69. Pfizer Gram-Negative Bacterial Infection Therapeutics Product

Table 70. Pfizer Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 71. Pfizer Recent Development

Table 72. Takeda Company Details

Table 73. Takeda Business Overview

Table 74. Takeda Gram-Negative Bacterial Infection Therapeutics Product

Table 75. Takeda Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 76. Takeda Recent Development

Table 77. Nektar Therapeutics Company Details

Table 78. Nektar Therapeutics Business Overview

Table 79. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Product

Table 80. Nektar Therapeutics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 81. Nektar Therapeutics Recent Development

Table 82. Sumitomo Company Details

Table 83. Sumitomo Business Overview

Table 84. Sumitomo Gram-Negative Bacterial Infection Therapeutics Product

Table 85. Sumitomo Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 86. Sumitomo Recent Development

Table 87. Targeted Genetics Company Details

Table 88. Targeted Genetics Business Overview

Table 89. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Product

Table 90. Targeted Genetics Revenue in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025) & (US$ Million)

Table 91. Targeted Genetics Recent Development

Table 92. Research Programs/Design for This Report

Table 93. Key Data Information from Secondary Sources

Table 94. Key Data Information from Primary Sources

Table 95. Authors List of This Report

List of Figures

Figure 1. Gram-Negative Bacterial Infection Therapeutics Picture

Figure 2. Global Gram-Negative Bacterial Infection Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Enteral Treatment Features

Figure 5. Parenteral Treatment Features

Figure 6. Topical Treatment Features

Figure 7. Global Gram-Negative Bacterial Infection Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Application: 2024 VS 2031

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Others Case Studies

Figure 12. Gram-Negative Bacterial Infection Therapeutics Report Years Considered

Figure 13. Global Gram-Negative Bacterial Infection Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Gram-Negative Bacterial Infection Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Region: 2024 VS 2031

Figure 16. Global Gram-Negative Bacterial Infection Therapeutics Market Share by Players in 2024

Figure 17. Global Top Gram-Negative Bacterial Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-Negative Bacterial Infection Therapeutics as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue in 2024

Figure 19. North America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2020-2031)

Figure 21. United States Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2020-2031)

Figure 25. Germany Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Gram-Negative Bacterial Infection Therapeutics Market Share by Region (2020-2031)

Figure 33. China Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2020-2031)

Figure 41. Mexico Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Market Share by Country (2020-2031)

Figure 45. Turkey Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Gram-Negative Bacterial Infection Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Baxter Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 49. Sanofi Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 50. GlaxoSmithKline Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 51. Novartis Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 52. Pfizer Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 53. Takeda Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 54. Nektar Therapeutics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 55. Sumitomo Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 56. Targeted Genetics Revenue Growth Rate in Gram-Negative Bacterial Infection Therapeutics Business (2020-2025)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Gram positive Bacterial Infection Drugs Market Research Report 2024

Global Enterobacteriaceae Infection Drug Market Research Report 2024

Global Microbial Antibacterial Drugs Market Research Report 2024

Global Klebsiella Pneumoniae Infection Drug Market Research Report 2024

Global Chlamydia Infection Therapeutics Market Research Report 2024

Global Bacterial Disease Diagnostics Market Insights Forecast to 2030

Global Antimicrobial Barrier Dressing Market Research Report 2024

Global Antimicrobial Technology Market Research Report 2024

Global Rotavirus Infection Therapeutics Market Research Report 2024

Multidrug Resistant Bacteria Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Gram Staining Market Research Report 2024

Global Bacterial Antigens Market Research Report 2024

Global Meningococcal Infections Treatment Market Research Report 2024

Global Clostridium Botulinum Infection Treatment Market Research Report 2024

Global Bacterial Protein Market Research Report 2024

Global Antibiotic Resistance Market Insights Forecast to 2030

Global Antimicrobial Topical Market Research Report 2024

Global Bacterial Vaginosis Therapeutics Market Insights Forecast to 2030

Global Peptide Antibiotics Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions